About
Bin Qiu is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. His research focuses on molecular mechanisms underlying metabolic disorders, neurobiology, and liver pathophysiology, with a particular emphasis on FKBP51 and Parkin protein interactions. Dr. Qiu holds a PhD from Peking University and a BS from Ocean University of China.
Research Interests: Dr. Qiu investigates the role of FKBP51 in mitochondrial function, synaptic plasticity, and sex-specific responses to alcohol. His work also explores metabolic pathways in nonalcoholic steatohepatitis (NASH), cardiovascular repair mechanisms, and antihypertensive peptide development. His studies combine molecular biology, genetics, and electrophysiology to address translational questions in pharmacology and neuroscience.
Recent Work Trends: Articles from 2022–2024 highlight advancements in understanding mitochondrial dysfunction in liver injury, sex differences in alcohol-induced neuroadaptations, and the role of Parkin in hippocampal health. Earlier work (2017–2019) addressed adipocyte differentiation, cardiac stem cell activation, and bone development through PP5 inhibition.
Professional Background: No awards explicitly listed, but his research has implications for therapies targeting metabolic and neurological diseases. No advising or grant details provided in the text. He is affiliated with Yale School of Medicine's Pharmacology department and contributes to collaborative initiatives in translational medicine.